Alivus Life Sciences

May 14 (Reuters) - Alivus Life Sciences Ltd ALIV.NS:

• ALIVUS LIFE SCIENCES LTD - RECOMMENDS FINAL DIVIDEND OF 5 RUPEES PER SHARE

• ALIVUS LIFE SCIENCES LTD - MARCH-QUARTER PROFIT 1.63 BILLION RUPEES

• ALIVUS LIFE SCIENCES LTD - MARCH-QUARTER REVENUE FROM OPERATIONS 6.89 BILLION RUPEES

Source text: ID:nBSE47PTCX

Further company coverage: ALIV.NS

(([email protected];))

Feb 25 (Reuters) - Alivus Life Sciences Ltd ALIV.NS:

• ALIVUS LIFE SCIENCES LTD - FIRE INCIDENT AT DAHEJ FACILITY ON FEBRUARY 14

• ALIVUS LIFE SCIENCES LTD - INCIDENT WAS CONFINED TO ONE BLOCK; API FACILITIES UNAFFECTED

• ALIVUS LIFE SCIENCES LTD - API PRODUCTION TO RESUME MARCH 1, INTERMEDIATES MID-MARCH

• ALIVUS LIFE SCIENCES LTD - TEMPORARY CESSATION WILL RESULT IN DELAYED SHIPMENTS

Source text: ID:nBSE5qTFFG

Further company coverage: ALIV.NS

(([email protected];))

Feb 16 (Reuters) - Alivus Life Sciences Ltd ALIV.NS:

• ALIVUS LIFE SCIENCES LTD - FIRE AT API PLANT IN DAHEJ, GUJARAT

• ALIVUS LIFE SCIENCES LTD - THREE INJURIES REPORTED; SITUATION CONTROLLED IN ONE HOUR

• ALIVUS LIFE SCIENCES LTD - COMPANY INVESTIGATING CAUSE AND ASSESSING DAMAGE

• ALIVUS LIFE SCIENCES LTD - PRODUCTION TEMPORARILY SUSPENDED DUE TO FIRE

Source text: ID:nBSE58rKYj

Further company coverage: ALIV.NS

(([email protected];;))

Jan 22 (Reuters) - Alivus Life Sciences Ltd ALIV.NS:

• Q3 PROFIT 1.5 BILLION RUPEES

• Q3 REVENUE FROM OPERATIONS 6.73 BILLION RUPEES

Source text: ID:nnAZN4S2NHI

Further company coverage: ALIV.NS

(([email protected];;))

July 3 (Reuters) - Dev Information Technology Ltd DEVN.NS:

• SECURES ORDER WORTH 44 MILLION RUPEES FROM ALIVUS LIFESCIENCES

Source text: ID:nBSE5zBkZN

Further company coverage: DEVN.NSALIV.NS

(([email protected];))

April 3 (Reuters) - Alivus Life Sciences Ltd ALIV.NS:

• ALIVUS LIFE SCIENCES LTD - USFDA ISSUES EIR WITH VAI STATUS FOR ANKLESHWAR FACILITY

Source text: ID:nBSEc8Tm9n

Further company coverage: ALIV.NS

(([email protected];))

April 2 (Reuters) - Alivus Life Sciences Ltd ALIV.NS:

• ALIVUS LIFE SCIENCES LTD - ENTERS AGREEMENT WITH TORRENT URJA 19

• ALIVUS LIFE SCIENCES LTD - TO ACQUIRE 9.21% STAKE IN TORRENT URJA 19

• ALIVUS LIFE SCIENCES LTD - ACQUISITION COST 156 MILLION RUPEES

Source text: ID:nBSE4XCM5P

Further company coverage: ALIV.NS

(([email protected];;))

Jan 23 (Reuters) - Alivus Life Sciences Ltd ALIV.NS:

• DEC-QUARTER PROFIT 1.37 BILLION RUPEES

• DEC-QUARTER REVENUE FROM OPERATIONS 6.42 BILLION RUPEES

Source text: [ID:]

Further company coverage: ALIV.NS

(([email protected];;))

** Shares of Glenmark Life Sciences GLEM.NS climb 3.5% at 971.20 rupees

** Brokerage Kotak Institutional Equities upgrades stock to "Buy" from "Reduce"

** GLEM's near-term outlook is intact as it continues to step up investments in capacity addition under Nirma, brokerage says

** Adds, new client wins in ts contract manufacturing segment, along with a rich API portfolio will be key growth drivers for the company in near term

** GLEM's stock fell 10% last week after downbeat Q2 results due to a temporary shutdown of its biggest manufacturing facility in Gujarat

** Analysts' avg rating on GLEM at "buy"; peers Laurus Labs LAUL.NS and Divi's Laboratories DIVI.NS rated "Hold" - LSEG data

** GLEM's ~48% YTD gain bigger than LAUL's ~15% climb but smaller than DIVI's ~49% rise

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

** Shares of Glenmark Life Sciences GLEM.NS drop 10% to 936.90 rupees

** Stock set for worst day ever if losses hold

** API maker's Q2 profit fell ~20% YoY, rev from ops down ~15% YoY

** GLEM said temporary closure of a manufacturing facility in Gujarat hurt revenue across geographies

** Trading volume at 2.1x the 30-day moving avg

** Analysts' avg rating on GLEM at "buy"; peers Laurus Labs LAUL.NS and Divi's Laboratories DIVI.NS rated "hold" - LSEG data

** GLEM's 43% YTD gain bigger than LAUL's ~10% climb but smaller than DIVI's ~48% rise

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

Oct 24 (Reuters) - Glenmark Life Sciences Ltd GLEM.NS:

• Q2 PROFIT 953.2 MILLION RUPEES

• Q2 REVENUE FROM OPERATIONS 5.07 BILLION RUPEES

Source text for Eikon: ID:nNSE6c2tF7

Further company coverage: GLEM.NS

(([email protected];;))

Oct 9 (Reuters) - Glenmark Life Sciences Ltd GLEM.NS:

• GLENMARK LIFE - CHANGE OF NAME OF CO TO "ALIVUS LIFE SCIENCES LIMITED"

Further company coverage: GLEM.NS

(([email protected];))

Aug 5 (Reuters) - Glenmark Life Sciences Ltd GLEM.NS:

• GLENMARK LIFE - STAKE OF PROMOTER IN CO REDUCED FROM 75.00073% TO 74.99982%

• GLENMARK LIFE - CO HAS BECOME COMPLIANT WITH MINIMUM PUBLIC SHAREHOLDING REQUIREMENTS

Source text for Eikon: ID:nNSE2WLXnt

Further company coverage: GLEM.NS

(([email protected];))

July 25 (Reuters) - Glenmark Life Sciences Ltd GLEM.NS:

• ISSUE OF CLOSURE NOTICE FOR OUR ANKLESHWAR FACILITY BY GPCB

• GUJARAT POLLUTION CONTROL BOARD ORDERED NOT TO CARRY PRODUCTION AT FACILITY

• ACTIVELY ENGAGED IN ADDRESSING MATTER

Source text for Eikon: ID:nBSE6j23fN

Further company coverage: GLEM.NS

(([email protected];))

July 4 (Reuters) - Glenmark Life Sciences Ltd GLEM.NS:

• GLENMARK - ENTERED INTO A LETTER AGREEMENT WITH GLENMARK PHARMACEUTICALS AND NIRMA

• GLENMARK LIFE - AGREEMENT AMENDS EARLIER SHARE PURCHASE AGREEMENT

• GLENMARK LIFE - AGREEMENT HAS WAIVED CONTRACTUAL RESTRICTION IMPOSED ON SELLER

• GLENMARK LIFE - IF SELLER IS NOT ABLE TO COMPLETE SALE OF SHAREHOLDING, RESTRICTIONS SHALL BE REINSTATED

• GLENMARK LIFE - RESTRICTION WAIVED TO FACILITATE COMPLIANCE WITH MINIMUM PUBLIC SHAREHOLDING REQUIREMENTS

Source text for Eikon: ID:nBSE3XqBzS

Further company coverage: GLEM.NS

(([email protected];))

BENGALURU, May 15 (Reuters) - Drugmaker Granules India GRAN.NS posted a 1.6% fall in fourth-quarter revenue on Wednesday, hurt by a decline in paracetamol sales and price erosion.

The company's consolidated revenue fell year-on-year to 11.76 billion rupees (nearly $141 million) for the three months to March 31.

Granules, which focuses on making active pharmaceutical ingredients (API), holds 30% of the global market for Paracetamol. It makes the drug's API as well as the finished dosage - the ready-for-consumption product.

Still, weak sales of the drug and price erosion due to heightened competition hurt its revenue. This is despite analysts expecting Indian API makers, including Granules, to benefit from increasing demand from Europe and the U.S., the industry's biggest markets.

Shares fell as much as 2.6% after it reported its results.

Rivals Glenmark Life Sciences GLEM.NS and Laurus Labs LAUL.NS posted lower fourth-quarter profits.

Glenmark's revenue was hit by issues stemming from the Red Sea crisis while Laurus was challenged by multiple factors including a decline in selling prices of antiretroviral products.

A 9.5% drop in Granules' raw material expenses, meanwhile, helped its quarterly profit climb 8.4% to 1.30 billion rupees.

API makers use a variety of chemicals in their formulations, including hydrochloric acid and chloroform, accounting for a majority of the drug-makers' input costs.

The easing costs had helped its profit marginally climb in the third quarter as well, before which profit fell for two straight quarters.

($1 = 83.4750 Indian rupees)

(Reporting by Varun Hebbalalu in Bengaluru; Editing by Janane Venkatraman )

(([email protected];))

** Shares of Laurus Labs LAUL.NS close 2% lower to 425.9 rupees

** Co's March-qtr profit fell roughly 26.6% YoY, its fifth straight quarterly profit drop

** Rival Glenmark Life Sciences GLEM.NS also posted Q4 profit drop on the day; its stock dropped after results

** Analysts' avg rating on LAUL stock is "hold", and is "buy" on GLEM - LSEG data

** LAUL flips to YTD loss, down 1% so far this year; GLEM up 18% from last year

(Reporting by Varun Vyas in Bengaluru)

(([email protected]))

** Shares of pharmaceutical firm Laurus Labs LAUL.NS rise as much as 7.9% to 448 rupees, highest since Nov. 28, 2022

** Stock on track for fourth consecutive session of gains

** Reuters could not immediately ascertain a reason for the move

** Stock top gainer in Nifty pharma index .NIPHARM, which is trading flat

** Stock most active since Jan. 25; more than 6.9 mln shares change hands by 1:59 p.m. IST, 3.9x the 30-day avg

** Avg rating of 10 analysts equivalent of "hold", median PT is 333 rupees - LSEG data

** Among peers, Granules India GRAN.NS rated "strong buy" while Glenmark Life Sciences GLEM.NS is rated "buy" - LSEG

** LAUL fell 8.8% in March quarter vs 12.9% rise in Nifty pharma index

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

March 12 (Reuters) - Glenmark Life Sciences Ltd GLEM.NS:

• NIRMA ACQUIRES MAJORITY STAKE IN GLENMARK LIFE SCIENCES

• NIRMA COMPLETES ACQUISITION OF 75% OF SHARE CAPITAL FROM GLENMARK PHARMACEUTICALS

Source text for Eikon: ID:nBSE1mNM9g

Further company coverage: GLEM.NS

(([email protected];))

March 6 (Reuters) - Glenmark Life Sciences Ltd GLEM.NS:

• GLENMARK LIFE SCIENCES LTD - GLENN SALDANHA TENDERED HIS RESIGNATION AS CHAIRMAN

Source text for Eikon: ID:nBSE1x5Yyz

Further company coverage: GLEM.NS

(([email protected];))

MUMBAI, Feb 21 (Reuters) - India's Nirma NIRMA.UL has accepted bids aggregating to 35 billion rupees ($422 million) for a three-part shorter-tenor bonds to fund its acquisition of a 75% stake in Glenmark Pharma's GLEN.NS life sciences unit, three bankers said on Wednesday.

Earlier in the day, the detergent maker had invited bids for bonds maturing in one year and two days, two years, one month and 16 days, and in three year, one month and 16 days.

The company will pay an annual coupon of 8.30%, 8.40% and 8.50%, respectively, to investors of the bond issue.

Axis Mutual Fund, ICICI Prudential Mutual Fund, HDFC Mutual Fund, Aditya Birla Finance, Aditya Birla Sun Life Mutual Fund, Kotak Mutual Fund, Nippon India Mutual Fund, SBI Mutual Fund were the anchor investors to the issue, according to bankers.

In September, Glenmark Pharma said it would sell a 75% stake in Glenmark Life Sciences GLEM.NS to Nirma for 56.52 billion rupees. The deal is expected to be completed in the current financial year. nL4N3AX38V

Crisil Ratings has assigned an "AA" rating for the proposed issue after factoring in the company's intent to diversify its business via the proposed acquisition.

The coupon will step up by 25 basis points for every notch downgrade in the ratings of the bonds.

Nirma last tapped the bond market in July 2022, when it raised 1 billion rupees via bonds maturing in 18 months at a coupon of 7.59%.

Here is the list of deals reported so far on Feb. 21:

*Size includes base plus greenshoe for some issues

($1 = 82.9270 Indian rupees)

(Reporting by Bhakti Tambe; Editing by Varun H K)

(([email protected]))

Jan 23 (Reuters) - Glenmark Life Sciences Ltd GLEM.NS:

• DEC-QUARTER PROFIT 1.19 BILLION RUPEES VERSUS 1.05 BILLION RUPEES

• DEC-QUARTER REVENUE FROM OPERATIONS 5.73 BILLION RUPEES VERSUS 5.41 BILLION RUPEES

Source text for Eikon: [ID:]

Further company coverage: GLEM.NS

(([email protected];))

** Shares of Glenmark Life Sciences GLEM.NS rise as much as ~3% to 778.90 rupees, their highest since Aug 2021

** The active pharmaceuticals ingredients (API) maker said it signed a deal to manufacture and supply API for a Japanese innovator pharma company

** Estimated commercial value of project at ~$5 mln

** Analysts avg rating on GLEM at "buy"; median PT is 715 rupees - LSEG data

** Stock rose about 56% in 2023

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

Glenmark Life Sciences Ltd GLEM.NS:

• COMPETITION COMMISSION OF INDIA APPROVES ACQUISITION OF MAJORITY SHAREHOLDING OF GLENMARK LIFE SCIENCES LIMITED BY NIRMA LTD - GOVERNMENT STATEMENT

Source text for Eikon: [ID:]

Further company coverage: GLEM.NS

Oct 20 (Reuters) - Glenmark Life Sciences Ltd GLEM.NS:

• SEPT-QUARTER REVENUE FROM OPERATIONS 5.95 BILLION RUPEES VERSUS 5.09 BILLION RUPEES

• SEPT-QUARTER PROFIT 1.19 BILLION RUPEES VERSUS 1.07 BILLION RUPEES

Further company coverage: GLEM.NS

(([email protected];))

BENGALURU, Oct 6 (Reuters) - Shares of Indian pharmaceutical company Valiant Laboratories VALO.NS rose 15.8% in their trading debut on Friday, valuing the company at 5.28 billion rupees ($63.5 million).

The initial public offering of the Mumbai-based maker of paracetamol tablets was oversubscribed 29.8 times, with retail investors bidding 16 times and high net-worth investors 73.6 times.

The offering had fresh issue of shares worth 1.62 billion rupees ($19.5 million) at the top end of the 133-140 rupees price range.

Valiant is involved in the business of manufacturing active pharmaceutical ingredients (API) for pain killer drug Paracetamol.

Valiant competes with larger rivals such as Granules GRAN.NS and Glenmark Life Sciences GLEM.NS in the API market.

Earlier this week, Indian commercial port operator JSW Infrastructure's JSWN.NS listing saw a bumper opening with shares surging more than 32%.

($1 = 83.2025 Indian rupees)

(Reporting by Sethuraman NR and Kashish Tandon in Bengaluru; Editing by Sohini Goswami)

(([email protected]; (+91 9945291420); Reuters Messaging: [email protected]))

Sept 21 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• APPROVED SALE OF 75.00% OF GLENMARK LIFE SCIENCES TO NIRMA

• DEAL FOR 615 RUPEES PER SHARE, AGGREGATING TO 56.52 BILLION RUPEES

• GLENMARK PHARMA WILL CONTINUE TO OWN 7.84% IN GLENMARK LIFE SCIENCES

• NIRMA WILL MAKE A MANDATORY OPEN OFFER TO ALL PUBLIC SHAREHOLDERS OF GLS

Source text for Eikon: ID:nBSE5SH31y

Further company coverage: GLEN.NS

(([email protected];))

BENGALURU, Aug 11 (Reuters) - India's Glenmark Pharmaceuticals Ltd GLEN.NS reported a 22% decline in quarterly profit on Friday, hit by higher expenses and a one-time cost.

Consolidated net profit fell to 1.50 billion rupees ($18.12 million) for the three months ended June 30, from 1.93 billion rupees a year ago, the cetrizine maker said.

Glenmark, which caters to therapeutic areas such as diabetes, cardiovascular and oral contraceptives, reported a 19% rise in total expenses to 30.37 billion rupees. This included a 86.7% spike in finance costs.

Expenses also increased due to a one-time cost of 520.2 million rupees spent during the quarter for repairs at its various manufacturing facilities in India and the United States.

The company's India drugs segment, which accounted for about 31% of total sales, rose by 2.8%, while its North America business, which contributed 23.8%, grew 22%. This helped net sales rise 22.6% to 33.36 billion rupees.

Last quarter, the company's revenue was hurt due to a lower demand in its India business.

Glenmark's rivals Dr Reddy's Laboratories REDY.NS and Cipla CIPL.NS had posted higher profits last month on stronger sales.

Last month, unit Glenmark Lifesciences Ltd GLEM.NS had posted a near 25% rise in first-quarter profit, helped by growth in its active pharma ingredient business.

Shares of the Mumbai-based company settled 1.1% lower on Friday ahead of its results. Glenmark Pharmaceuticals' shares had climbed 45.5% in the April-June quarter, outperforming the Nifty Pharma index .NIPHARM that rose 14.6%.

($1 = 82.7960 Indian rupees)

(Reporting by Biplob Kumar Das in Bengaluru; Editing by Shailesh Kuber)

(([email protected]; 9101861583;))

Aug 3 (Reuters) - Glenmark Life Sciences Ltd GLEM.NS:

• NEWS REPORT ON CHRYSCAPITAL IN RACE TO BUY CO IS SPECULATIVE IN NATURE

• THERE IS NO INFORMATION CURRENTLY WITH COMPANY THAT IS REPORTABLE

Source text for Eikon: ID:nBSE6YWfgS

Further company coverage: GLEM.NS

(([email protected];))

July 21 (Reuters) - Glenmark Life Sciences Ltd GLEM.NS:

• PROCESS OF SELLING A PART OF GLENMARK PHARMACEUTICALS STAKE IN GLENMARK LIFESCIENCES IS ON

• GLENMARK PHARMACEUTICALS IS RUNNING THE SALE PROCESS

• WE’RE CONTRIBUTING TO THE SALE PROCESS, WHEREEVER REQUIRED

• GLENMARK PHARMACEUTICALS IS RUNNING THE SALE PROCESS

Source text for Eikon: [ID:]

Further company coverage: GLEM.NS

(([email protected];))